PT-141 (Bremelanotide) Manufacturer Bridge Programs

What Is Bremelanotide (PT-141) and Why Does It Cost So Much?

Bremelanotide is the active pharmaceutical ingredient in Vyleesi, the only FDA-approved pharmacologic treatment for acquired, generalized HSDD in premenopausal women [1]. Palatin Technologies developed the compound as a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It binds melanocortin receptors MC1R and MC4R in the central nervous system rather than acting peripherally on vascular smooth muscle, which distinguishes it mechanistically from phosphodiesterase-5 inhibitors used in male sexual dysfunction [2].

The high list price reflects patent protection and the relatively small patient population for which it is labeled. Single-source branded drugs with orphan-adjacent market sizes routinely exceed $800, $1,200 per unit in the U.S. Market, and Vyleesi sits within that range. Insurance coverage has been inconsistent: many commercial plans require prior authorization, and Medicaid coverage varies by state formulary [3].

The RECONNECT Trial and Regulatory Basis

The FDA approval rested on two key Phase 3 RECONNECT trials (combined N=1,267 premenopausal women with HSDD). Bremelanotide 1.75 mg produced a statistically significant increase in the number of satisfying sexual events (SSEs) compared with placebo (P<0.001 in both studies) and a significant reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [4]. The FDA label was granted June 21, 2019, under NDA 210557 [1].

Why Payers Resist Coverage

A 2020 analysis published in the Journal of Sexual Medicine noted that HSDD affects an estimated 5.4 to 13.6% of premenopausal women in the United States [5]. Despite that prevalence, many insurers classify bremelanotide as a "lifestyle" drug, applying coverage restrictions analogous to those placed on testosterone products prescribed for female sexual dysfunction. The American College of Obstetricians and Gynecologists (ACOG) has noted that such restrictions create disparate access compared with coverage of male sexual dysfunction treatments [6].

The Vyleesi Manufacturer Savings Card Program

Palatin Technologies offers a co-pay savings card through the Vyleesi brand website. Commercially insured patients who are eligible may reduce their out-of-pocket cost to as low as $0 per prescription, subject to monthly and annual benefit caps that Palatin periodically revises.

Key eligibility rules as of mid-2025:

• The patient must have commercial (private) insurance. Medicare, Medicaid, and other federal or state government-funded plans are excluded by law from manufacturer co-pay assistance.
• The prescriber must submit the claim through a participating specialty pharmacy or retail chain.
• The card cannot be combined with any other coupon, rebate, or patient assistance offer.

How to Activate the Savings Card

1. Obtain a valid prescription from a licensed prescriber.
2. Visit the Vyleesi official site or request an enrollment form through the prescriber's office.
3. Submit the card at the pharmacy alongside the insurance claim. The card covers the gap between insurance payment and the patient's co-pay responsibility, up to the program cap.

Palatin's savings program structure is similar to co-pay assistance programs documented across branded specialty drugs; a 2022 JAMA Internal Medicine analysis found that manufacturer co-pay cards reduced median patient cost by 64% on affected prescriptions, though they simultaneously increased total plan spending [7].

Program Limitations

Savings card programs can change or end with little advance notice. Patients who rely on the card for ongoing therapy should verify current terms directly with Palatin or the dispensing pharmacy before each refill. The FDA does not regulate the terms of manufacturer assistance programs, so benefit amounts are entirely at Palatin's discretion [1].

Patient Assistance Programs (PAPs) for Uninsured and Underinsured Patients

For patients without commercial insurance or whose insurance denies coverage, Palatin administers a patient assistance program (PAP) that provides Vyleesi at no or reduced cost based on financial need.

Income and Documentation Requirements

Most branded pharmaceutical PAPs require applicants to meet household income thresholds, typically expressed as a percentage of the federal poverty level (FPL). Common cutoffs across the industry range from 200% to 400% FPL, though exact figures differ by program and change annually. Applicants generally must provide:

• Proof of U.S. Residency
• A completed prescriber attestation form
• Recent income documentation (tax return, pay stubs, or Social Security award letter)
• Denial letter from insurance if applicable

How to Apply

Applications are submitted through the Vyleesi Access Support program. Prescribers or their office staff can initiate enrollment on behalf of the patient. Specialty pharmacies contracted with Palatin often support the paperwork. Processing time is typically 2 to 4 weeks, though urgent need pathways can accelerate this.

Because PAP availability and income limits shift with each fiscal year, patients should confirm current criteria through Palatin's medical affairs line or through a pharmacist certified in specialty medication access. The National Alliance of State Pharmacy Associations maintains guidance on PAP navigation that is publicly available [8].

Compounding Pharmacies: PT-141 as a Lower-Cost Alternative

PT-141 refers to the peptide bremelanotide in its research and compounded forms, predating the Vyleesi brand. Licensed 503A compounding pharmacies in the United States prepare bremelanotide for patients with a valid individualized prescription. Compounded preparations are not FDA-approved, are not bioequivalent-verified to Vyleesi, and carry different risk profiles compared with the branded product [9].

Cost Comparison

Compounded bremelanotide typically costs $50, $200 per vial (containing multiple doses) through telehealth platforms and specialty compounding pharmacies, versus roughly $990, $1,080 for a single-dose Vyleesi auto-injector kit. The cost differential is substantial, which drives significant off-label demand.

Regulatory Status of Compounded Bremelanotide

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare drugs based on a valid patient-specific prescription even when an FDA-approved version exists. Bremelanotide does not appear on FDA's 503B "essentially a copy" list as of the date of this review, meaning 503A pharmacies can prepare it under current enforcement policy. Patients and prescribers should verify pharmacy accreditation through the Pharmacy Compounding Accreditation Board (PCAB) [9].

The FDA has published guidance clarifying that compounded drugs are not FDA-approved and have not undergone FDA review for safety, efficacy, or manufacturing standards [9]. Prescribers bear additional clinical responsibility when directing patients to compounding sources.

Dosing Differences in Compounded Formulations

Compounded PT-141 is most commonly supplied as a lyophilized powder reconstituted with bacteriostatic water, administered subcutaneously at doses ranging from 1.0 mg to 2.0 mg. The FDA-approved Vyleesi delivers exactly 1.75 mg per auto-injector. Dose titration flexibility is one reason some clinicians prefer compounded formulations for patients who experience nausea (reported in 40.1% of Vyleesi-treated patients in RECONNECT vs. 1.2% placebo [4]) at the full 1.75 mg dose [10].

HSA and FSA Eligibility for PT-141

Bremelanotide prescribed for HSDD is a qualified medical expense under IRS Publication 502, making it eligible for payment from a Health Savings Account (HSA) or Flexible Spending Account (FSA) [11].

How HSA/FSA Payment Works

Both HSA and FSA funds can be applied at the pharmacy counter using a dedicated debit card, or patients can pay out-of-pocket and submit reimbursement claims. The prescription must be written by a licensed provider for a legitimate medical diagnosis (HSDD, coded as F52.0 in ICD-10-CM) for the expense to qualify [12].

The CARES Act of 2020 permanently expanded FSA/HSA eligibility to include many prescription medications that had previously required a physician's letter of medical necessity. Bremelanotide requires a prescription by law, which automatically satisfies the qualification standard under current IRS guidance [11].

Combining HSA/FSA With Other Discounts

HSA and FSA funds can be used to pay the remaining patient balance after a manufacturer savings card has been applied. However, using an HSA/FSA card to pay expenses that have already been fully covered by a co-pay assistance card is not permitted under IRS rules, since the expense must represent an unreimbursed qualified medical cost [11]. Patients should work with their benefits administrator to confirm stacking eligibility.

Prior Authorization Navigation and Step Therapy

Many commercial plans require prior authorization (PA) for Vyleesi. Some also require step therapy, meaning a documented trial of a cheaper alternative such as flibanserin (Addyi, the only other FDA-approved HSDD drug) before approving bremelanotide [13].

Documenting Medical Necessity

A strong PA submission should include:

• DSM-5 or ICD-10 diagnosis documentation for HSDD (F52.0)
• Clinical notes from a gynecologist, urologist, or psychiatrist attesting to symptom duration, severity, and impact on quality of life
• Evidence that non-pharmacologic options (sex therapy, relationship counseling) were considered
• Documented reason for not using flibanserin if step therapy applies (e.g., alcohol interaction risk, hepatic enzyme concerns)

The FDA label for flibanserin carries a boxed warning about severe hypotension and syncope when combined with alcohol, a safety concern that many prescribers cite when bypassing step therapy requirements for bremelanotide [13].

Appeals and Peer-to-Peer Review

If the initial PA is denied, prescribers can request a peer-to-peer review with the plan's medical director. Published data from the Kaiser Family Foundation show that 59% of all PA appeals resolved in the patient's favor in 2022 [14]. A well-documented appeal, supported by RECONNECT trial data and ACOG committee opinions on equitable access to sexual health treatments, has a reasonable chance of success [6].

Telehealth Platforms and Subscription Models

Several telehealth companies specializing in sexual health now prescribe bremelanotide and dispense compounded PT-141 through affiliated pharmacies. These platforms often bundle the consultation fee, medication, and ongoing monitoring into a monthly subscription ranging from $80 to $250.

What Telehealth Models Offer

• Asynchronous consultations (questionnaire-based) are fastest but provide less individualized clinical assessment.
• Synchronous video visits with a licensed provider offer higher safety screening, including blood pressure assessment (transient hypertension and nausea are the most common adverse effects of bremelanotide [4]).
• Auto-refill programs reduce adherence friction. Because Vyleesi is dosed on-demand rather than daily, auto-refill cadence should be based on anticipated use frequency rather than a fixed monthly schedule.

The HealthRX clinical team has developed a four-step access framework for bremelanotide that prioritizes patient safety alongside cost reduction:

Step 1. Screen for HSDD using a validated tool such as the FSDS-DAO or the HSDD Screener for Women (HSDD-SW) and confirm the diagnosis with ICD-10 F52.0.

Step 2. Check commercial insurance formulary. If covered with manageable co-pay, apply the Vyleesi savings card at the dispensing pharmacy.

Step 3. If uninsured or underinsured, apply for the Palatin PAP. If ineligible for PAP, consider PCAB-accredited 503A compounding pharmacy with dose titration starting at 1.0 mg to reduce nausea risk.

Step 4. Regardless of source, use HSA/FSA funds to cover any remaining unreimbursed out-of-pocket cost.

Nausea Management: A Cost-Related Clinical Point

The 40.1% nausea rate in the RECONNECT trials [4] led a measurable proportion of patients to discontinue Vyleesi. Discontinuation translates directly into wasted drug cost. Evidence-based strategies to reduce nausea include pre-dosing with a 5-HT3 antagonist such as ondansetron 4 mg orally 30 minutes before injection, and starting with a compounded 1.0 mg dose to assess individual tolerance before escalating [10]. A 2021 review in the Journal of Clinical Pharmacology confirmed that MC4R agonism at lower doses maintains CNS efficacy signals while reducing emetic side effects in dose-ranging studies [10]. Reducing nausea means patients complete more courses of therapy, improving both outcomes and cost efficiency.

Blood Pressure Monitoring Requirements

Bremelanotide transiently elevates blood pressure. In RECONNECT, mean peak increases were approximately 6 mmHg systolic and 3 mmHg diastolic within 12 hours of dosing [4]. Vyleesi is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension, per the FDA label [1]. The American Heart Association guidelines for hypertension management recommend against initiating drugs that raise blood pressure in patients with Stage 2 hypertension (systolic above 140 mmHg) without consulting the managing cardiologist first [15]. Telehealth prescribers should obtain a baseline blood pressure measurement before prescribing and document it in the medical record.

Off-Label Use in Men and Its Access Implications

The FDA approved bremelanotide only for premenopausal women with HSDD. Off-label use in men for erectile dysfunction or low libido lacks FDA-approved status, meaning manufacturer co-pay assistance programs almost certainly will not cover prescriptions written for male patients, and insurance coverage is effectively unavailable. Compounding pharmacies represent the primary access pathway for male patients pursuing off-label bremelanotide. Prescribers bear full clinical and legal responsibility for off-label prescribing and should document the clinical rationale, review the available evidence, and obtain informed consent [9]. Phase 2 data from a Palatin-sponsored trial (NCT00428779) in men with erectile dysfunction showed statistically significant improvements in erectile function versus placebo (P<0.05) but the program was not advanced to Phase 3 [16].

Insurance Coverage by Plan Type

Commercial Insurance

Coverage ranges widely. Plans on the ACA marketplace have inconsistent formulary placement. Employer-sponsored plans with pharmacy benefit managers (PBMs) often place Vyleesi on Tier 3 or Tier 4, generating co-pays of $150, $400 per kit before savings card application.

Medicare

Medicare Part D does not cover drugs approved exclusively for sexual dysfunction, per the statutory exclusion in the Social Security Act Section 1927(d)(2). This exclusion applies to Vyleesi [3].

Medicaid

State Medicaid programs are not required to cover Vyleesi. As of 2024, fewer than 15 state Medicaid formularies include bremelanotide, and those that do typically require PA. The CMS Medicaid drug coverage database is the primary source for state-level formulary lookups [3].

TRICARE and VA

TRICARE does not currently list Vyleesi on its formulary. The VA formulary also excludes it under the sexual dysfunction drug exclusion. Veterans and active-duty personnel would need to access bremelanotide through civilian compounding channels at out-of-pocket cost.

Practical Steps to Get Bremelanotide at the Lowest Possible Cost in 2025

1. Confirm HSDD diagnosis with ICD-10 F52.0 documentation.
2. Request a formulary check from the prescriber's office before the prescription is sent.
3. Apply for the Vyleesi savings card immediately upon prescription approval if commercially insured.
4. If the savings card still leaves a balance, apply remaining HSA/FSA dollars to that balance.
5. If uninsured or denied coverage, apply directly to Palatin's PAP through the prescriber's office.
6. If PAP is unavailable or processing takes too long, ask the prescriber about PCAB-accredited 503A compounding sources with dose titration starting at 1.0 mg.
7. Document all PA denials and request a peer-to-peer appeal. Over half of appeals succeed [14].
8. Recheck savings card terms at each refill. Program caps and eligibility rules change annually.